Should You Forget Realty Income and Buy Healthpeak Properties Instead?

Realty Income (O) continues to demonstrate a durable income profile with its 667th consecutive monthly dividend, 133 increases since 1994, a ~4.2% dividend CAGR, a >5% yield, a sub-75% payout ratio and a diversified 15,400-property net-lease portfolio supported by one of the stronger REIT balance sheets; it deployed over $6 billion last year. Healthpeak Properties (DOC) converted to monthly dividends last April, raised payouts 1.7% after a 2020 cut, yields ~6.8%, carries a ~71% payout ratio and an investment-grade balance sheet, and is pursuing a Janus Living senior-housing IPO (H1) plus ~$925m of transactions and $675m of new senior-housing investments to unlock portfolio value and potentially drive near-term upside. The tradeoff for investors is higher current yield and activation-driven upside at Healthpeak versus Realty Income’s steadier, lower-risk dividend growth runway.

Analysis

Market structure: Winners are Healthpeak (DOC) and lab-focused landlords; DOC’s 6.8% yield plus active capital recycling (>$900m transactions and $675m new senior-housing pipeline) positions it to capture outsized re‑rating if Janus IPO (H1 2026) prices well. Realty Income (O) retains defensive demand and pricing power across 15,400 net‑lease assets with a ~5% yield, favoring income-seeking allocators but limiting near-term upside. Outpatient assets sellers and private buyers benefit from bid/ask mismatches; lab supply remains tight in coastal gateways, supporting rents 5–10% above secondary markets over 12–36 months.

Risk assessment: Key tail risks are a poorly received Janus IPO (equity raise < $400m or >15% repricing), a senior‑housing occupancy shock (10–20% downside to NOI) or a 75–100bp faster move up in 10‑yr yields that could compress REIT multiples 10–25%. Immediate (days) volatility will cluster around S‑1/IPO news; short term (weeks–months) risks hinge on capital recycling execution; long term (quarters–years) depends on lab demand and demographic trends. Hidden dependencies: DOC’s dividend resilience assumes proceeds from disposals and steady lab leasing; weakness in private bids or lab oversupply is second‑order but material.

Trade implications: Tactical: establish a 2–3% long in DOC now to capture re‑rating into Janus IPO (target +20–30% in 6–12 months; stop −15%). Core income: add 3–4% position in O for stable monthly yield; offset by selling 6–9 month covered calls ~5–7% OTM to increase carry. Pair trade: long DOC / short O (1:1 notional) for 6–12 months to capture valuation spread; hedge rate risk by buying 2s10s steepener protection or buying 6–12 month 10‑yr Treasury calls if yield moves >50bp.

Contrarian angles: Consensus underweights the possibility that Janus IPO could unlock >25% of NAV for senior‑housing assets if priced to growth, creating upside more than currently implied by the 6–7% yields. Conversely, the market may be underpricing downside: if DOC retires cashflow into a spun IPO without recapitalizing dividends, downside could exceed 30% — a scenario many investors ignore. Historical parallels: REIT spin‑offs (e.g., post‑financial crisis healthcare restructurings) show volatile short‑term pricing but durable long‑term bifurcation between stabilized triple‑net portfolios and operator‑exposed senior housing.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Healthpeak (DOC) ahead of the Janus Living IPO (target H1 2026); objective: capture a 20–30% re‑rating within 6–12 months; implement a hard stop at −15% and trim half at +20%.
• Add a 3–4% core long in Realty Income (O) for stable monthly income; write 6–9 month covered calls ~5–7% OTM to raise yield (target incremental 2–3% annualized income) and roll if exercised.
• Run a relative‑value pair: long DOC / short O (1:1 notional) sized 1–2% net exposure for 6–12 months to exploit dividend yield spread and re‑rating optionality; hedge interest‑rate tail risk by buying a 2s10s steepener or 6–12 month 10‑yr call if yields rise >50bp.
• Buy a cost‑limited upside via options: purchase a 9–12 month DOC call spread (ATM long, ~30% OTM short) sizing to 0.5–1% notional to express upside while capping premium; if S‑1 shows weak IPO proceeds (<$400m) or covenant deterioration, close within 7 trading days.